- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05714683
Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea
April 30, 2024 updated by: Novo Nordisk A/S
A Multi-centre, Prospective, Open-label, Single-arm, Non-interventional, Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus® (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea
The aim of this study is to assess the safety and effectiveness of Rybelsus initiated according to label in adults with Type 2 Diabetes Mellitus (T2DM) under routine clinical practice conditions.
Participants will get Rybelsus as prescribed by study doctor.
The study will last for about 26 weeks.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
600
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Novo Nordisk
- Phone Number: (+1) 866-867-7178
- Email: clinicaltrials@novonordisk.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
N/A
Sampling Method
Probability Sample
Study Population
Adult participants with T2DM, who initiate treatment with Rybelsus under routine clinical practice in Korea.
Description
Inclusion Criteria:
- The decision to initiate treatment with commercially available Rybelsus has been made by the participant/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study
- The participant with T2DM is scheduled to start treatment with Rybelsus based on the clinical judgment of their treating physician as specified in the approved label in Korea
- Informed consent is obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study
- Male/female age greater than or equal to (>=) 19 years at the time of signing informed consent
Exclusion Criteria:
- Participants who are or have previously been on Rybelsus therapy
- Known or suspected hypersensitivity to Rybelsus, the active substance or any of the excipients
- Previous participation in this study. Participation is defined as having given informed consent in this study
- Female participant who is pregnant, breast-feeding or intends to become pregnant and is of child-bearing potential and not using adequate contraceptive methods (adequate contraceptive measures as required by Korea regulation or practice)
- Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
- Family or personal history of multiple Endocrine Neoplasia Type 2 (MEN 2) or Medullary Thyroid Carcinoma (MTC)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Participants with T2DM
All participants will be treated with Rybelsus for 26 weeks according to routine clinical practice at the discretion of the treating physician according to the label approved by Ministry of Food and Drug Safety (MFDS).
|
All participants will be treated with oral semaglutide for 26 weeks according to routine clinical practice at the discretion of the treating physician according to the label approved by MFDS.
The prescription of semaglutide will be separated from the decision to include the participant in the study.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number (Incidence) of adverse events (AEs)
Time Frame: From baseline (week 0) to 26 weeks
|
Measured as count of events.
|
From baseline (week 0) to 26 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in body weight
Time Frame: From baseline (week 0) to 26 weeks
|
Measured in kilogram (kg).
|
From baseline (week 0) to 26 weeks
|
Number (Incidence) of hypoglycaemia Level 3 or Level 2
Time Frame: From baseline (week 0) to 26 weeks
|
Hypoglycaemia Level 3 or Level 2 according to American Diabetes Association (ADA) guideline 2020 refers to: 1) Level 2: Glucose less than (<) 54 milligrams per deciliter (mg/dL) (3.0 millimoles per liter [mmol/L]); 2) Level 3: A severe event characterized by altered mental and/or physical status requiring assistance for treatment of hypoglycaemia.
Measured as count of events.
|
From baseline (week 0) to 26 weeks
|
Change in glycated haemoglobin (HbA1c)
Time Frame: From baseline (week 0) to 26 weeks
|
Measured in percentage (%).
|
From baseline (week 0) to 26 weeks
|
Participants achieving HbA1c target <7.0%
Time Frame: At 26 weeks
|
Measured as count of participants (Yes/No).
|
At 26 weeks
|
Change in fasting blood glucose (FBG)/fasting plasma glucose (FPG)
Time Frame: From baseline (week 0) to 26 weeks
|
Measured in mg/dL.
|
From baseline (week 0) to 26 weeks
|
Change in post prandial blood glucose (PPBG)/post prandial plasma glucose (PPPG)
Time Frame: From baseline (week 0) to 26 weeks
|
Measured in mg/dL.
|
From baseline (week 0) to 26 weeks
|
Dose of Rybelsus
Time Frame: At 26 weeks
|
Measured in milligrams per day (mg/day).
|
At 26 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
December 31, 2024
Primary Completion (Estimated)
October 30, 2026
Study Completion (Estimated)
October 30, 2026
Study Registration Dates
First Submitted
January 27, 2023
First Submitted That Met QC Criteria
January 27, 2023
First Posted (Actual)
February 6, 2023
Study Record Updates
Last Update Posted (Actual)
May 1, 2024
Last Update Submitted That Met QC Criteria
April 30, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NN9924-4652
- U1111-1243-9500 (Other Identifier: World Health Organization (WHO))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Diabetes Foundation, IndiaNational Diabetes Obesity and Cholesterol FoundationRecruitingType 2 Diabetes Mellitus With ComplicationIndia
-
DiabeloopUniversity Hospital, Grenoble; AGIR à Dom; Icadom; Centre Hospitalier Annecy Genevois and other collaboratorsCompletedDiabetes Mellitus Type 2 - Insulin-TreatedFrance
Clinical Trials on Semaglutide
-
Novo Nordisk A/SCompletedObesity | OverweightUnited States, India, Japan, Russian Federation, United Kingdom, Canada, Spain, South Africa, Germany, Greece, United Arab Emirates, Argentina, Puerto Rico
-
Novo Nordisk A/SCompletedObesity | Diabetes Mellitus, Type 2 | OverweightKorea, Republic of, Hong Kong, Brazil, China
-
Novo Nordisk A/SCompletedObesity | OverweightUnited States
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2Germany
-
Novo Nordisk A/SCompletedType 2 Diabetes | Healthy VolunteersUnited States, Canada
-
Novo Nordisk A/SRecruiting
-
Sansum Diabetes Research InstituteNovo Nordisk A/STerminatedDiabetes Mellitus, Type 2 | Glucose Metabolism Disorders (Including Diabetes Mellitus)United States
-
Novo Nordisk A/SCompletedObesity | OverweightUnited States, Italy, Spain, Canada, Hungary
-
Novo Nordisk A/SCompletedObesity | OverweightJapan, Korea, Republic of
-
Novo Nordisk A/SCompletedOverweight or Obesity | Metabolism and Nutrition DisorderUnited States, India, Mexico, Russian Federation, United Kingdom, Canada, Denmark, Finland, Belgium, Japan, Taiwan, France, Poland, Germany, Bulgaria, Argentina, Puerto Rico